RespireRx Pharmaceuticals Inc (CE) (RSPI) News

No problem , i was just asking was that from 2019

The point is that Lippa likely was a substantial beneficiary of that sale.

Thats from the deal in 2019 correct

Lippa's DOV Pharmaceuticals:

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by means of a tender offer. The consideration consists of an upfront payment of USD 27.50 per share in cash ...

Hang on folks, I suspect we are in for quite a ride.

Obviously we have a financial web concerning RSPI that is not on the books. Hmmm.... could one or more of these private funds be holding substantial amounts of RSPI stocks?

Mr. Margolis and Dr. Lippa founded and jointly managed, since 2004, Atypical BioCapital Management LLC and Atypical BioVentures Fund LLC,

Arnold S. Lippa was the founder of Patch International, Inc. (founded in 1984) where he held the title of President & Chief Operating Officer from 1984 to 1994. He was also the founder of DOV Pharmaceutical, Inc. (founded in 1995) where he served as a Director from 2005 to 2006. He is the founder of T.Morgen Capital LLC (founded in 2005) where he currently holds the title of Senior Managing Director. Furthermore, he is the founder of Xintria Pharmaceutical Corp. (founded in 2006) where he currently serves as the Executive Chairman. Lastly, he is the founder of Atypical BioCapital Management LLC (founded in 2004) where he currently holds the title of Manager.

Dr. Lippa's current job(s) include being the Executive Chairman, President & CEO at RespireRx Pharmaceuticals, Inc. since 2013 and the President of Aurora Capital LLC since 2005.

Dr. Lippa's former job(s) include being a Director-Molecular Neurobiology at Wyeth Holdings LLC, an Independent Director at Hepion Pharmaceuticals, Inc. from 2015 to 2023, and a Professor at City University of New York and New York University School of Medicine.

I suspect RSPI is not cash starved

It is too hard to predict exactly how this would trade.

Depends on if back on the OTC or are they possibly looking at some M&A to get off the OTC and on a more institutional exchange like NASDAQ? Without any filings we dont know where fully diluted status could be either. I roughly thought around 1.5 billion shares, but could be more with any additional small financings, could be less if the convertibles are somehow bought out in whatever structure the assets land in.

Supposedly the OSA program is independently valued at 20+ million and possibly "multiples" of that. We can speculate what a phase 2 SCI drug is worth, especially with DOD funding the clinical. As well as what KRM-ll-81 could be worth at phase1 stage for epilepsy, and possibly pain indications as well especially with grant funding. For a stock like this with 3 platforms at clinical stage with really a robust history of preclinical and clinical efforts, well IMO these are very valuable now heading into clincals. 3 pennies, 5 or 10+ pennies all plausible. I think the bigger valuation leap comes in 2026-2027 as results of clinical efforts come in and obviously need to be positive results. I'll keep a majority of my stack for that risk v reward scenario.

One woud have to assume that they understand the potential lost opportunities from collaborations and resources and impact of time erosion on assets with a non-chalant do nothing time period. Frustrating as an investor.

Id say id we get back on the market we open above 01 fomo will drive us close to 03 then fall back to 02 or a lil below and start our raise to a nickle and above once further updates and deals are posted as confirmed 

Going to be tough for the FOMO crowd as they generally can’t buy on EM unless Canadian account I guess.

By the time this trades with liquidity either on OTC or another exchange, the market might have this valuation corrected to a more reasonable level considering multiple platforms in clinicals…

I mean if the SCI trial is successful, value significantly increases as that will likely lead into ADHD trials. But if KRM-ll-81 is successful in phase 1, that will exponentially leap valuations as both epilepsy and pain/opioid mitigation are Huge markets needing better solutions.. Certainly BP has been looking at this neuromodulator platform. Could be huge assets to develop for a BP.

So building out resources and investor base would help smoothly transition the clinical phases which adds value!! Delay and dragging feet deplete value! Financial strength and flexibility adds significant value as well for obvious reasons.

Short term this has massive ROI potential just getting back on track, but longer term 2026-2027 clinical trial success can yield beyond imagination.. IMO

I am sure investors and all stakeholders alike are not looking for excuses and explanations. It is only logical and the significant progress/position of their platforms and the CEO comments about opening "purse strings" and all their commentary in past filings... logical that they went silent to get their house in order and that includes handling the debt, structuring the assets and negotiating with funding sources including BP.

As Catpole suggests, quite possibly there is an NDA or some type of silence agreement in play. At this point that is a logical assumption and a very good thing for shareholders as when they come out of this there is likely to be funding and resources in place to take these assets from say 50-100 million valuation to 5x that upon success in any of the upcoming clinical trials.

Yet this move to the expert market, dancing around filing responsibilites, lack of any updates and proper communication and presentation, etc, etc... well they should know by now what investors and stakeholders think of that strategy... Get this train on the rails and lets see these drugs flourish in clinicals!!

When communicating with Jeff CEO and Paul from the investor agent , My point blank question was if they were investors looking would they invest in RSPI based on the last 6 months and the actions they have showed is it a good look. No replie on answering it directly but both noted it is a concern they hope to explain and direction forward in the letter
IMO I think they are waiting on a few more goals and positive reults and then we see what this company will be going forward.
Stay safe for all that are in the weather storm forecast for the next couple of days , and positive thoughts for the fire victims GLTA

macroaxis.com:

"The fear of missing out, i.e., FOMO, can cause potential investors in RespireRX Pharmaceuticals to buy its pink sheet at a price that has no basis in reality. In that case, they are not buying RespireRX because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell pink sheets at prices well below their value during bear markets because they need to stop feeling the pain of losing money."

I can’t imagine them dragging their feet too much longer.. at this pace the patents will expire and new technology will trump in long before the insiders get any ROI on their loans or equity stakes, let alone payment events that unlock preferred or get any investment money back…

The stock has long ago consolidated into true long investor hands, not otc fanatics… lol. So get on with the show! Time erodes..

But it will be interesting if a letter emerges. There should have been one the next day after moving to the EM!!

You bring up a good point though with your pharma comparison. Most pharmas trade at high expectant valuations before and during clinicals, only to have failure drop it like a rock. RSPI is starting at rock bottom, Before heading into multiple clinical trials… with zero effort to address valuation. Shall we conclude they got the goods!!! Rock to Rocket!!

Yes look at this one , over the past 1 year. flying high then a bad result . SYRS Syros Pharmaceuticals Inc , I think the right results and news we could see SP in the dollars. This company doesnt have what we have been told RSPI has at look at their SP even today. Jeff was saying he was getting there , and was trying to explain everything good bad and what they have challeging left to get over and gives us what they want to get done in 2025. Hopefully they do have BP lined up and maybe it is a Buyout and the main players are kept on and running the show. Who knows GLTA

Remember how many times we thought the same thing over a 4 year span in ENZC?

UIC and the VA (sponsor) are collaborating on a phase 1/2 dronabinol trial in a few months according to notes on clinical site. I wonder how this connects?

Agree. I suppose BP/institutional won’t deploy capital until ready to start clinical trials. I suppose to they are likely waiting on extent of grant funding for KRM-ll-81. Confirmation of clinical starting/additional grants will set the stage for infusion of capital/resources..

These pharma turn on a dime and can run like crazy over a few months..

"In particular, we were highly dependent on Timothy L. Jones, our CEO and President who resigned effective January 31, 2022, and are highly dependent on Arnold S. Lippa, Ph.D., Interim CEO and Interim President, since the resignation of Mr. Jones, who is our Chief Scientific Officer and Executive Chairman, and Jeff E. Margolis, our Senior Vice President, Chief Financial Officer, Treasurer and Secretary."

https://www.sec.gov/ix?doc=/Archives/edgar/data/0000849636/000149315222010053/form10-k.htm

Modified: March 21, 2022 at 9:34:39 PM EDT

I suspect we hear more as the trials either begin or continue. Many irons in the fire and should be of interest to big Pharma. My experience is that NDA' can be frustrating to investors as they remain in the dark until the NDA agreement ends. We can only hope that positive movement is being made, and communication comes as per Jeff, "near future". In the meantime, I just sit with my considerable number of shares and hope the lid is blown off very soon.
I have much interest in the potential treatment for pain as I have experience four joint replacements and multiple heart procedures. I hated coming off the addictive pain killers. I guess I could also state I have interest in potential sleep medication as I use a CPAP.

I have thought that from the get-go as it makes sense and it fits the logic of them not parlaying the DOD news and advancement in NIH preclinicals into significant investor interest that would have easily funded filings and thensome. Allowing this much time to now pass with zero communication and updates on anything or on the company presentation is a bit confirming in my mind. They likely have a plan in place for funding and supporting clinicals. Whether institutional investors or BP come aboard or all of the above who knows...

Excited to see the clinicals get going as it will open many doors for investors and patients needing treatments.

I sincerely hope that is the case otherwise this whole operation has been severely mismanaged 

My thought is that RSPI is under a non-disclosure agreement with a major player. This quiet period along with moving to the expert market may indicate something big is coming our way.

https://www.google.com/url?client=internal-element-cse&cx=ee84a120178161b02&q=https://diagramresearch.com/phases-of-clinical-trials/&sa=U&ved=2ahUKEwiah-Oxxv2KAxU0MEQIHY1uLHoQFnoECAwQAQ&usg=AOvVaw3uMPYl60y2UwTcxs_SBbcN&fexp=72821495,72821494

Excellent overview of the phases in Clinical Trials.

Hopefully any forthcoming update is comprehensive and outlines a strategy for getting these assets into a liquid trading environment.

One thing they have continually mentioned, (yet there has been little fanfare related) is the spinning out of the neuromodulator platform EndearvourRx. Considering both the leads in the ampakine and gabakine platforms are at clinical stage and with government level funding, the time is certainly ripe for this business unit to stand-a-lone with capital to assist the push through current clinical stages and prepare the resources for future clinicals and to expand efforts in other medical indications.

I don't think it would surprise anyone if this is the source of the silence and the move to the EM as they possibly iron out how this all is structured.

Imagine what EndeavourRx could be worth and how many doors could open to expanding the platforms, helping patients with unmet needs!!

Tim Jones has is no longer with RespireRX. Seems he left in 2022. Dr. Arnold Lippa is now president and CEO.
Just wish Dr. L would give us the promised shareholder update.

That is 2021

Hey folks - just came across this: https://www.otcmarkets.com/files/OTCQBPodcast_RespireRx_Season5Episode44.pdf Couldn't find a date, but looks to be fairly recent.

Been asking that question since they dissappeared onto this expert market...... lol

I did notice that the transfer agent has not updated share count for a few months now. Previously I believe that was done weekly....

Hopefully they are getting ready for a move to establish a liquid market so funding and resource building can begin and exploit these assets as they advance in clinicals... unlocking their potential and value...

Wondering...

Given all the progress of 3 different platforms now at various clinical trial stages AND all the past commentary about their assets/pipeline, etc...

What do the insiders and executives think RSPI is worth today?

Less than 1 million trading on this EM?
~5 million like the 2024 price peak?
20-40 million suggested as what solely the OSA program is worth?
100+ million with government funding multiple trials on 3 different clinical stage platforms?

How do you factor in distinguishing preclinical positive results on potential breakthrough medicine for epilepsy, pain, SCI, OSA, ADHD... huge markets with unmet needs! Billion dollar potential in a few years with positive clinical momentum??

So, what’s going on?

Curious: this was e-published last September, I guess officially today.

Clin Pharmacol Drug Dev . 2025 Jan;14(1):50-58.
doi: 10.1002/cpdd.1475. Epub 2024 Sep 20.
Safety, Tolerability, and Pharmacokinetic Profile of the Low-Impact Ampakine CX1739 in Young Healthy Volunteers

Daniel P Radin, Rok Cerne, Jeffrey M Witkin, Arnold Lippa

PMID: 39302241 DOI: 10.1002/cpdd.1475

Abstract
AMPA-type glutamate receptors (AMPARs) mediate the majority of fast excitatory synaptic transmission in the mammalian brain. Ampakines, positive allosteric modulators of AMPAR, hold significant potential for the treatment of a wide range of neurological/neuropsychiatric disorders in which excitatory synaptic transmission is compromised. Low-impact ampakines are a distinct subset of ampakines that accelerate channel opening yet minimally affect receptor desensitization, which may explain their lack of seizurogenic effects at therapeutic doses in preclinical models. CX1739 is a low-impact ampakine that has shown efficacy in preclinical studies. The current clinical study examined the tolerability and pharmacokinetics of CX1739 in healthy male volunteers in a 2-part study. Part A was a single dose escalation study (100-1200 mg, 48 patients) and Part B was a multiple dose ascending study (300-600 mg BID for 7-10 days, 32 patients). CX1739 was well tolerated up to 900 mg once daily (QD) and 450 mg twice a day, with the prominent side effects being headache and nausea. Importantly, the half-life of CX1739 was 6-9 hours, and Tmax was 1-5 hours. CX1739 Cmax and AUC were dose-proportional. These findings thus set the stage for further explorations of this drug candidate in phase 2 clinical studies.

You get an L
And you get an L

and you get an L

Thanks for sharing… everything help at this point. Have a great day DT! 💪🏻

Well, I believe they valued their OSA program at around 20 million and I believe a comment was made they thought it was really multiples of that. But we have not heard a peep about that program for over a year, so who knows what is stagnating that.

I consider the ampakine program CX1739/CX717 basically as 1 compound with possible multiple indications. The SCI market is not near as big as if they potentially get these into ADHD trials. I think the ampakine platform has some negative stigma associated with past mistakes and toxicity of high impact ampakines. Hence why I think the publication effort to distinguish the difference between high and low impact ampakines. They are at phase 2 stage so that does increase the value versus preclinical stage. Regardless, having the DOD now fund a phase 2 with any success exponentially increasing value is worth a chunk of change one would imagine.

IMO, KRM-ll-81 may be the most valuable asset. Exiting preclinicals, where presumably it has shown to be superior to standard of care at preclinical stage AND with huge target markets of both pain and epilepsy, well IMO this would lean heavily towards the higher end of valuation for a preclinical drug.

Most OTC investors can name several pharma and biotech stocks that at one point traded for 100s of millions with much less of a pipeline with much less of a robust preclinical effort attached and much less of a science team behind it. And here the market cap today is less than 1 million!!!

The lack of valuing your assets and your efforts fairly surely significantly limits the ability to attract resources in terms of talent and collaborators as well as attract funding and partnerships that will be necessary to smoothly transition through the various stages of development. Constant delays, stagnation, lack of this or that only serves to devalue the assets long-term as patents eventually expire, competitors are continually developing new technology, etc, etc..

Well, from what I can figure, there are at least 5 different preclinical and early clinical phase molecules. So, by AI, RSPI pipeline is worth 250 to 500 M or .25 to .50 a share. Hell, by that calculation, 1000 to 3000% profit ain't too bad! Then add the irrational exuberance ... the sky's the limit. What fun to dream!

Agree. Hence why sec filings and PR, interviews, commentary are more important due diligence efforts.

Interesting though asking AI what are preclinical drugs worth...
"The valuation of a preclinical drug can range significantly, but generally falls between $15 million and $100 million depending on factors like the drug's potential therapeutic value, the stage of preclinical development, and the company's overall financial standing; with most preclinical companies being valued in the range of a Series A round, typically between $40 - $100 million. "

It probably takes a lot of patience to allow your company/assets to sit so far undervalued, yet takes the smarts to utilize the government funding programs... i.e. DOD, NIH, etc to absorb early stage costs. We can argue the merits of multiple platforms moving into clinical trials and therapeutic value, resources, etc, etc, but trading less than 1 million market cap is quite a disconnect.

I am a member of Muck Rack, a proprietary journalist website. About a year ago muckrake.com inquired of members to evaluate AI for assistance in research and writing. I inputted "stealth lynching" and got a beautifully written, on the surface a well researched paragraph. Had me going for a few minutes before I realized that all the references were bogus. There is no such term. Be careful with AI.

Always interesting as to what AI search tools can cobble together on a topic. In regards to KRM-ll-81, I think the simplest due diligence is reading the publications and watching the CEO interview from early last year. Remembering that Lippa is a scientist/researcher and not a pure CEO personality the commentary I find to be genuine and meaningful.....

Calling it a "remarkable drug" and that it works in every single animal model of pain.. Collaborating with NIH and their data shows "it works" and CEO hoping purse strings open to support development. Moved into final stages of NIH preclinicals (tier 3) and subsequently we hear of the hiring of a consultant group for managing grant funding for epilepsy indication.. Curious though the intent of the NIH preclinicals was pain mitigation based and no word on if the consultant group is also seeking grant funding for this indication as well... OR is there another interested party for KRM-ll-81 pain indication only? I do believe you can JV/license drug development for specific indications, not sure on that.

Given the history of both the ampakine platform and the OSA program as well known... The gabakine platform and a drug with superior preclinical profile could be worth a gold mine and maybe is the source of the silence here??? Either way, KRM-ll-81 coupled with the ampakine and OSA assets are severly undervalued and I expect at some point in the not too distant future these assets will be valued properly as stakeholders, insiders, retail shareholders down to patients who need these medicine advancements have so much to gain by seeing these assets be given the resources to succeed and not stagnate further. In my opinion and GLTA.

AI Overview
Learn more
The outlook for KRM-II-81 under RespireRx appears positive, with preclinical studies showing promising potential as a novel treatment for pharmacoresistant epilepsy due to its ability to suppress epileptiform activity in brain slices from patients with treatment-resistant epilepsy, alongside demonstrating significant analgesic effects with minimal side effects like sedation or tolerance development, making it a potential new drug for managing severe pain conditions as well.
Key points about KRM-II-81:
Mechanism of Action:
KRM-II-81 acts as a positive allosteric modulator of the a2/3-containing GABA receptor, enhancing its activity and leading to increased inhibitory neurotransmission, which could be beneficial in managing seizures and pain.
Preclinical efficacy:
Studies in animal models of pharmacoresistant epilepsy have shown KRM-II-81 to be effective in suppressing seizures with minimal side effects compared to standard antiepileptic drugs.
Patient tissue studies:
Research has demonstrated KRM-II-81's ability to suppress hyperactivity in cortical slices from patients with pharmacoresistant epilepsy, further supporting its potential clinical translation.
Pain management potential:
Preclinical data also indicates KRM-II-81's analgesic properties, showing significant pain relief without the associated risks of opioid dependence or respiratory depression.
Potential challenges:
Clinical trials needed:
While preclinical results are promising, further clinical trials are required to confirm efficacy and safety in human patients.
Regulatory pathway:
Navigating the regulatory process for a new drug can be complex and time-consuming.
Overall, KRM-II-81 under RespireRx holds significant potential as a new treatment option for patients with pharmacoresistant epilepsy and potentially other pain conditions based on its preclinical data demonstrating potent anti-seizure and analgesic effects with a favorable safety profile.
Structural Analogs of the GABAkine KRM-II-81 Are Orally ...
Laboratory of Antiepileptic Drug Discovery, St. ... KRM-II-81 is active in models predicting efficacy in pharmacoresistant epileps...
National Institutes of Health (NIH) (.gov)
RespireRx Pharmaceuticals Inc. Announces Publication of ...
Nov 30, 2021 — (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that scientists associated with the Company have ...

BioSpace
RespireRx Pharmaceuticals Inc. Announces a Department of ...
May 29, 2024 — In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM- II-81 to dr...

RespireRx
Show all
Generative AI is experimental.

I asked Google Gemini about KRM-ll-81? The A.I. almost seemed like it was excited for all of the potential this drug has.

It said that given any kind of FDA approval that this would significantly change the direction of this company.

If anyone has Google Gemini asked the A.I. about KRM-II-81 under RespireRX.

It is long overdue for them to address all stakeholders and get this thing back on the rails.

Too much potential to remain stagnant.

Letter is not to far off , will address comments / concerns , the good and bad of 2024 , 2025 plans , ect.. should be an informational letter. GLTA

Lt - eventually we will see. With all that is going on with RSPI, I am still struck by CX929 as being important potentially in RSPI's pipeline in that it was administered orally, nontoxic by that administration mode and efficacious. But of course, right now it does not appear to be in focus.

I can see that potential with KRM-ll-81 post all the NIH preclinical activities. Might be alot of interested parties with that one.

I think the ampakines have been out there a long time and the high-impact ones are not under any RSPI patents any further and from what is on the website and I think reported from company their focus is solely on the low impact ones for SCI then ADHD. Would love to see a new tech revive the high impact ones, but RSPI needs to accomplish so much else before they could even imagine having resources branching out.

LT - I am not working for pharma, but I sure am aware of the neuorpharma literature. The literature is massive on ampakines reporting extraordinary preclinical findings on, as you know, multiple fronts. Big pharma must be aware of this literature. They are likely coming to RSPI, not the other way around.

With no communication and lack of updated information on that "website", and trading on the EM, it would be hard to make a first impression to prospective investors....

Definitely not acting like a company who is looking for investors....

Nor is my daughter's firm, but she is still there for the week. All speculation, one way or the other, we will hopefully get clarification soon.